Beam Therapeutics Inc. Contract with Customer, Liability, Noncurrent
Beam Therapeutics Inc. (BEAM) had Contract with Customer, Liability, Noncurrent of $0 as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2026-02-24
- 2025-12-31: Contract with Customer, Liability, Noncurrent $0.00.
- 2025-09-30: Contract with Customer, Liability, Noncurrent $10.16M.
- 2025-06-30: Contract with Customer, Liability, Noncurrent $20.32M.
- 2025-03-31: Contract with Customer, Liability, Noncurrent $49.40M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 |
| 2025-09-30 | $10.16M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $20.32M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $49.40M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $33.22M 10-K · filed 2026-02-24 |
| 2024-09-30 | $57.82M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $75.49M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $99.57M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $109.89M 10-K · filed 2025-02-25 |
| 2023-09-30 | $124.65M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $156.20M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $171.71M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $202.18M 10-K · filed 2024-02-27 |
| 2022-09-30 | $198.29M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $208.82M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $225.09M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $262.30M 10-K · filed 2023-02-28 |
| 2021-09-30 | $36.82M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $40.38M 10-Q · filed 2021-08-10 |
| 2020-12-31 | $394.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |